Phase IIA trial testing erlotinib as an intervention against intraductal pancreatic mucinous neoplasms.
Journal: Cancer Prev Res (Phila)
Date: 2011 Apr
Major Program(s) or Research Group(s): GOCRG, CONSORTIA
PubMed ID: 21464031
PMC ID: PMC4492452
Abstract: Intraductal papillary mucinous neoplasms (IPMN) are a distinct type of precursor lesions that cause about 5% of pancreatic adenocarcinoma (1, 2). Four-year survival rates of 40% to 75% are reported (3-7). There is currently no chemotherapy specifically approved for treating IPMNs. The number of IPMN cases has significantly increased over the last decade (8).